Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2002 April;43(2) > The Journal of Cardiovascular Surgery 2002 April;43(2):175-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

ORIGINAL ARTICLES  CARDIAC SECTION 

The Journal of Cardiovascular Surgery 2002 April;43(2):175-9

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Intravenous allicin improves pulmonary blood flow after ischemia-reperfusion injury in rats

Batirel H. F. 1, Naka Y. 1, Kayano K. 3, Okada K. 3, Vural K. 4**, Pinsky D. J. 3, Oz M. C. 2

From the 1 Department of Thoracic Surgery Marmara University Hospital, Istanbul, Turkey 2 Division of Cardiothoracic Surgery Department of Surgery 3 Division of Circulatory Physiology Department of Cardiology Columbia Presbytarian Medical Center New York, New York, New York, USA 4 Division of Cardiovascular Surgery Yüksek Ihtisas Hospital, Ankara, Turkey


PDF


Background. Allicin is a sul­fur-con­tain­ing com­pound extract­ed ­from gar­lic, ­with anti­ag­greg­a­to­ry, ­anti- migra­to­ry, ­anti-oxi­dant ­and pul­mo­nary vaso­di­la­tor ­actions. We hypoth­e­sized ­that alli­cin ­might be ben­e­fi­cial in ­lung ischemia-reperfusion.
Methods. A ­non-nother­mic ­rat ­lung ischemia-reperfusion mod­el ­was estab­lished by clamp­ing ­left pul­mo­nary ­artery (PA) ­for 1 hr, fol­lowed by reper­fu­sion ­for 2 ­hrs by clamp­ing ­right PA to ­reflect sole­ly ­the func­tion of ­left ­lung. Groups ­were con­trol (n=7), alli­cin 0.1 ­mg (n=8) ­and alli­cin 0.01 ­mg (n=4). In ­the begin­ning of reper­fu­sion allicin/­saline ­were inject­ed. Pulmonary ­artery pres­sures (­PAP), pul­mo­nary ­artery ­flow (­PAF), ­left atri­al pres­sure (­LAP) ­were mon­i­tored. At ­the ­end of reper­fu­sion peri­od arte­ri­al ­blood ­gas (ABG) anal­y­sis ­was ­done.
Results. Six of 7 con­trol ­and 3 of 8 ­group 2 ani­mals ­died ­before com­plet­ing ­the experi­ment. In ­group 1 ­all ani­mals com­plet­ed ­the experi­ment (p=0.015 vs con­trol). ­PAF ­was sig­nif­i­cant­ly ­increased ­after 30, 60 ­and 120 ­min of reper­fu­sion in ­group 1 (p=0.0028, 0.0009, 0.0003 respec­tive­ly vs con­trol) ­and ­after 60 ­and 120 min­utes in ­group 2 (p=0.0453, 0.018 respec­tive­ly vs con­trol). Pulmonary vas­cu­lar resis­tance ­was low­er at 30 ­min in allicin 0.01 ­mg ­group (p=0.0017 vs con­trol). ­PAP ­was ­increased ­after 60 ­and 120 ­min of reper­fu­sion in ­group 1 (p=0.016, 0.0029 respec­tive­ly vs con­trol) ­and ­after 120 ­min in ­group 2 (p=0.0104 vs con­trol).
Conclusions. This ­study ­shows ­that allicin ­improves ­postischem­ic ­PAF in ­this mod­el. Allicin ­needs fur­ther inves­ti­ga­tion of poten­tial util­ity ­and mech­a­nism(s) of ­action.

inizio pagina